U.S. stock market midday update: Creative Medical Tech down 15.77%, received a 440% bullish rating from analysts

U.S. Stock Market Midday Update

Creative Medical Tech fell 15.77%. Based on recent key news:

1. On June 30, trading activity for Creative Medical Technology Holdings significantly increased, with a trading volume of 86 million shares, while the company's three-month average daily trading volume was about 147,000 shares. This surge in trading volume may reflect the market's heightened attention to the company's future developments, leading to significant stock price fluctuations.

2. On June 30, analyst Jonathan Aschoff from Roth MKM rated Creative Medical Technology Holdings as "Moderate Buy" and set a target price of $20, indicating a potential upside of 440.54%. However, the market's reaction to this rating may not have met expectations, resulting in a decline in stock price.

3. On June 30, the company's forward-looking statement mentioned upcoming clinical trials and laboratory results, which may raise investor concerns due to these uncertainties, affecting stock price performance. The market remains vigilant about the volatility of biotechnology stocks.

Top Stocks by Industry Trading Volume

Abivax SA rose 1.56%. Based on recent key news:

1. On July 1, Abivax announced the launch of a public offering of American Depositary Receipts, leading to a rise in stock price. This offering aims to raise approximately $800 million to support the potential commercialization and clinical development of obefazimod in the U.S. This news drove the stock price up.

2. On June 30, Abivax released supplemental data from the Phase III clinical trial of obefazimod, alleviating market concerns about cancer risk and safety, causing the stock price to soar over 40%. The latest data indicated that the incidence of malignancies was similar to that of general ulcerative colitis patients, further confirming safety.

3. On July 1, Abivax's common stock resumed trading on Euronext Paris after being suspended due to the pricing and investor allocation related to the public offering of American Depositary Receipts. After resuming trading, the stock price increased. The biotechnology sector has shown strong performance recently, with significant capital inflows.

AbbVie fell 0.69%. Based on recent key news:

1. On July 1, a U.S. congressional committee is investigating AbbVie's clinical trials conducted in mainland China, particularly those conducted at locations associated with the Chinese military. This news has raised market concerns about the company's potential risks, leading to a decline in stock price.

2. On June 30, AbbVie reported that its collaboration with Nxera Pharma achieved its fourth research and development milestone, with Nxera receiving a $10 million milestone payment. Although this news is favorable for the company's long-term development, it failed to boost the stock price On June 29, AbbVie's partner Regenxbio administered an experimental gene therapy to patients for the first time in mid-to-late stage studies, receiving a milestone payment of $100 million. Although this news is favorable for the partner, it did not significantly impact AbbVie's stock price. The biotechnology industry has shown recent volatility, and investors should exercise caution.

Can-Fite BioPharma rose 42.42%. Based on recent key news:

1. On July 1, Can-Fite BioPharma announced that its Phase 2a study evaluating Namodenoson for the treatment of patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival results. This positive news significantly boosted the stock price.

Trading volume increased, with noticeable capital inflow.

Stocks ranked among the top in industry market capitalization

Amgen fell 0.17%, with increased trading volume. Based on recent key news:

1. On June 30, clinical trial data for Amgen's drug Tavneos was retracted, impacting drug sales. The European Medicines Agency recommended the withdrawal of the drug's market authorization, putting pressure on the stock price.

2. On June 30, Amgen was ordered to pay $60.6 million for patent infringement. This ruling may affect the attractiveness of its technology licensing and increase market uncertainty.

3. On June 28, Amgen's drugs Corlanor and Sensipar were recalled by the FDA. The recall may affect the company's reputation and market confidence. The biopharmaceutical industry faces patent and regulatory challenges